Streetbeat News

Stock Prices

NSP

Insperity has raised its FY24 outlook, adjusting its EPS guidance. The company now expects adjusted EPS to be between $3.33 and $3.88, compared to the previous range of $3.17 to $3.90 and the consensus estimate of $3.65. GAAP EPS guidance has been revised to $2.18 to $2.73, up from $2.02 to $2.75, against the consensus estimate of $2.59.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:07 pm

LIPO

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced a $1.28 million registered direct offering of 2,066,000 shares of common stock at $0.62 per share. The offering is expected to close on August 1, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:07 pm

GWW

W.W. Grainger has updated its 2024 guidance, narrowing its earnings per share (EPS) outlook to $38.00-$39.50 from the previous $38.00-$40.50, and its revenue forecast to $17.0-$17.3 billion from the prior $17.2-$17.7 billion. The company also adjusted other financial metrics, including sales growth, operating margin, and share buyback plans.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

CRAI

CRA Intl (NASDAQ:CRAI) reported Q2 2024 adjusted EPS of $1.83, beating the $1.50 estimate by 22%. Sales were $171.442M, surpassing the $168.253M estimate by 1.90%. This represents a 28.87% increase in EPS and a 5.85% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

AY

Atlantica Sustainable reported Q2 2024 GAAP EPS of $0.18, missing the $0.36 estimate. However, sales were $328.262M, beating the $326.447M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:06 pm

MRK

Daiichi Sankyo and Merck have announced the dosing of the first patient in the Phase 3 IDeate-Lung02 trial. This trial is evaluating Ifinatamab Deruxtecan for relapsed small cell lung cancer compared to chemotherapy.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:05 pm

K

Kellanova has raised its FY24 organic basis net sales growth guidance from 3%+ to 3.5% and increased its adjusted EPS guidance from $3.55-$3.65 to $3.65-$3.75.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:04 pm

RBLX

Roblox has provided its Q3 2024 guidance, forecasting revenue between $860 million and $885 million, which is below the $898 million estimate. The company also expects bookings between $1 billion and $1.025 billion, a consolidated net loss between $(275) million and $(255) million, and adjusted EBITDA between $22 million and $42 million. Net cash provided by operating activities is expected to be between $147 million and $162 million, with free cash flow between $105 million and $120 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:04 pm

OPTT

Ocean Power Technologies (NYSE:OPTT) has announced a patent pending for its new docking and recharging buoy technology designed for the Wave Adaptive Modular Vessel (WAM-V) Unmanned Surface Vehicle (USV). This innovation enhances the operational efficiency and range of USVs, making it valuable for oceanographic research, environmental monitoring, and defense applications.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:04 pm

DTIL

Precision BioSciences reported having approximately $123.6 million in cash and cash equivalents as of June 30, with a cash runway expected to last into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:03 pm